January 28, 2025 – The “Company” is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge – Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC’s innovative application of artificial intelligence (AI) and machine learning to advance early detection of Alzheimer’s disease (AD) and improve patient outcomes.
The PREPARE Challenge, sponsored by the NIA, encourages novel approaches for early AD detection using AI-driven tools that improve accuracy, affordability, and accessibility for patients. As a finalist, IGC developed prediction methods for Alzheimer’s disease and related dementias (AD/ADRD) using AI to analyze acoustic biomarkers derived from voice recordings.
Ram Mukunda said: “Being named a top 15 finalist reflects IGC Pharma’s leadership in leveraging cutting-edge AI technology to address critical gaps in Alzheimer’s care,” said Ram Mukunda, CEO of IGC Pharma. “Our approach applies multilingual AI models that enhance predictive accuracy, but also ensure cultural relevance across diverse populations including English, Spanish, and Chinese speakers. Our work to address disparities in early detection of Alzheimer’s can ultimately improve outcomes for patients worldwide.
This recognition by the NIA aligns with our broader mission to integrate AI with pharmaceutical innovation in Alzheimer’s care. Beyond diagnostics, our AI-driven solutions are designed to optimize treatment efficacy, ultimately creating long-term value for patients, healthcare systems, and shareholders alike.”
In the next stage of the competition, IGC Pharma will showcase the ability of its AI model to identify cognitive changes across diverse demographic groups. If selected as one of the three winners, the next phase of the challenge will consist of improving interpretability which can provide actionable insights for healthcare providers while maintaining a high level of transparency.
With over 7 million Americans living with Alzheimer’s and the global Alzheimer’s diagnostic market projected to exceed $10 billion by 2028, early detection represents a critical unmet need. By advancing to the Top 15 finalists, IGC Pharma demonstrates its commitment to innovation in leveraging AI for the early diagnosis of neurodegenerative diseases.
About IGC Pharma S.A.S.
IGC Pharma SAS is at the forefront of integrating artificial intelligence (AI) into drug discovery, clinical research, and early disease detection. We are committed to revolutionizing the pharmaceutical landscape by leveraging AI-driven solutions to enhance Alzheimer’s disease (AD) research, biomarker identification, and patient diagnostics.
Our team of biomedical engineers, data scientists, and clinical researchers utilizes advanced AI models to accelerate drug development, optimize clinical trials, and improve early detection of neurodegenerative diseases. We apply cutting-edge deep learning techniques to analyze vast datasets, uncover novel therapeutic targets, and refine treatment strategies.
With a strong foundation in AI-powered analytics, IGC Pharma SAS is dedicated to pioneering the next generation of precision medicine, ensuring that breakthroughs in neuroscience and drug discovery translate into effective, accessible treatments for patients worldwide.
Join us in reshaping the future of healthcare through the power of AI.
